GSE151412 In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma
Conclusions: We have completed a novel drug resistance screen in vivo, and identified that LXR agonism potentiates the efficacy of sorafenib in treating HCC.
Publication date: Available online 13 July 2020Source: Journal of Advanced ResearchAuthor(s): Jong Hyun Lee, Chakrabhavi Dhananjaya Mohan, Amudha Deivasigamani, Young Yun Jung, Shobith Rangappa, Salundi Basappa, Arunachalam Chinnathambi, Tahani Awad Alahmadi, Sulaiman Ali Alharbi, Manoj Garg, Zhi-Xiu Lin, Kanchugarakoppal S. Rangappa, Gautam Sethi, Kam Man Hui, Kwang Seok Ahn
Authors: Zheng YJ, Li DL, Luo, Chen XP, Zhang B, Fang C, Gan Y, Li B, Su S Abstract OBJECTIVE: Here, we aimed to compare early hepatectomy (EH) with delayed hepatectomy (DH) as a treatment for spontaneously ruptured hepatocellular carcinoma (HCC). METHODS: Several databases were systematically searched for eligible studies that compared DH with EH for spontaneously ruptured HCC treatment. Studies that met the inclusion criteria were reviewed systematically, and the reported data were aggregated statistically, using the RevMan v5.3 software. RESULTS: Seven studies were included, with a total of 385 patients,...
The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group (p
Conclusions: Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC. PMID: 32655640 [PubMed]
Nonalcoholic fatty liver disease (NAFLD) is becoming a major health issue as obesity increases around the world. We studied the effect of a circadian locomotor output cycles kaput (CLOCK) mutant (ClkΔ19/Δ19) protein on hepatic lipid metabolism in C57BL/6 Clkwt/wt and apolipoprotein E–deficient (Apoe−/−) mice. Both ClkΔ19/Δ19 and ClkΔ19/Δ19 Apoe−/− mice developed a full spectrum of liver diseases (steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma) recognized in human NAFLD when challenged with a Western diet, lipopolysaccharide, or CoCl2. We...
ConclusionsThe CUAs for CHC were found to apply to various HSUVs from different utility elicitation studies in the same health state. This variability in HSUVs has the potential to significantly affect ICER and ICER-based reimbursement decisions. A rigorous selection of HSUVs in CUAs to inform healthcare resource allocation is suggested for future studies of CUAs and for guideline development.
In conclusion, combination of sorafenib + pravastatin was safe and well-tolerated, prolonging the TTP of patients with aHCC but not improving the OS compared to sorafenib + placebo. The absence of PVT and VI and the development of DE are positive prognostic factors of sorafenib response.